Drug Transporter (DT) Information

General Information of DT
DT ID DTD0142
Gene Name SLC22A16
Protein Name Fly-like putative transporter 2
Gene ID
85413
UniProt ID
Q86VW1
TCDB ID
2.A.1.19.12
3D Structure

Modelled DT Structure

Method: multi-sequence alignment based machine learning

Detail: Structure Info

Synonyms OCT6; CT2; Carnitine transporter 2; FLIPT2; Flipt 2; HEL-S-18; OKB1; Organic cation transporter OKB1; SLC22A16; Solute carrier family 22 member 16; dJ261K5.1; Organic cation/carnitine transporter 6
DT Family Major Facilitator Superfamily (MFS)
Organic Cation Transporter (OCT) Family
Tissue Specificity Widely expressed at low levels in adulttissues and fetal brain, lung, liver and kidney. Expressed intestis and epididymis (at protein level). Expressed at lowerlevels in bone marrow and fetal liver. Expressed in hematopoieticcells, including CD34(+) leukocytes and leukemia cells. Abundantlyexpressed in ovarian cancer clear-cell adenocarcinoma. Expressedin endometrium (at protein level); highly expressed during thenormal secretory phase, but expression is significantly reduced inthe proliferative phase.
Function This sodium-ion dependent transporter mediates the uptake of carnitine. Also transports organic cations such as tetraethylammonium (TEA) and doxorubicin. Thought to mediate the L-carnitine secretion mechanism from testis epididymal epithelium into the lumen which is involved in the maturation of spermatozoa. The uptake of TEA is inhibited by various organic cations.
Disease(s) Nutritional deficiency [ICD-11: 5B7Z]
Endogenous Substrate(s) Carnitine
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:            2 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Doxorubicin
 Approved Drug Info Leukemia 2A60-2B33 [1]
L-carnitine
 Approved Drug Info Nutritional deficiency 5B7Z [2]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
L-carnitine
10917
EM Info Identified using oocytes of xenopus laevis-OCT6 [3]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
L-carnitine Approved Drug Info Oocytes-FLIPT2 Km = 20 microM [4]
References
1 Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
2 The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem. 2010 Feb 26;285(9):6275-84.
3 Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007 Jul;24(7):1227-51.
4 Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem. 2002 Sep 27;277(39):36262-71.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.